Clinical trial

Nab-Paclitaxel in Patients With ER+/HER2- Recurrent Metastatic Breast Cancer

NCT04194684

Study summary

ClinicalTrials.gov

Nab-Paclitaxel in Patients With ER+/HER2- Recurrent Metastatic Breast Cancer

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention nab-paclitaxel Find medicine records · Find other trials using this name

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2019-12-28

PhasePHASE2

Conditions

Breast Cancerverified · MONDO: breast cancer

Interventions

nab-paclitaxelDRUG

Sponsors & collaborators

Chinese Academy of Medical Scienceslead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04194684 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.